Phase II study of PM60184 in patients with advanced colon-rectal cancer after standard treatment.
Ontology highlight
ABSTRACT: Primary objectives: To evaluate the efficacy of PM060184 in terms ofprogression-free survival at 12 weeks (PFS3) in patients withadvanced colorectal carcinoma (CRC) after standard therapy.
Primary endpoints: PFS3, defined as the percentage of patients remaining aliveand progression-free at Week 12 (Month 3) after the firsttreatment dose.
DISEASE(S): Cáncer Colorectal Avanzado,Colorectal Cancer,Advanced Colorectal Cancer
PROVIDER: 2536604 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA